Emergent BioSolutions Reports Financial Results for Second Quarter and First Six Months of 2010

[...] throughout the remainder of 2010 and into 2011, we anticipate significant news flow as we focus on achieving our key upcoming milestones, which include: a follow-on procurement contract for BioThrax doses; a contract for the advanced development of our rPA program; FDA's response to our p...

Full description

Saved in:
Bibliographic Details
Published inBusiness Wire
Format Newsletter
LanguageEnglish
Published New York Business Wire 05.08.2010
Subjects
Accounts receivable
Administrative expenses
Anthrax
Financial performance
Net income
Product development
R&D
Research & development
Vaccines
Webcasting
ROCKVILLE, Md
Online AccessGet full text

Cover

More Information
Summary:[...] throughout the remainder of 2010 and into 2011, we anticipate significant news flow as we focus on achieving our key upcoming milestones, which include: a follow-on procurement contract for BioThrax doses; a contract for the advanced development of our rPA program; FDA's response to our pending submission for a revised dosing schedule for BioThrax of three doses over six months with a three year booster; completion of the ongoing clinical trial for AIG; initiation of a Phase I study for our next generation anthrax vaccine based on BioThrax and a novel adjuvant; initiation of a Phase I study for our anthrax monoclonal therapeutic; initiation of an additional Phase IIb study of our TB vaccine in HIV-infected subjects; and completion of an acquisition or in-licensing transaction to broaden our product development pipeline.